Arcutis Biotherapeutics, Inc. ARQT
We take great care to ensure that the data presented and summarized in this overview for Arcutis Biotherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARQT
View all-
Suvretta Capital Management, LLC New York, NY11.5MShares$170 Million5.56% of portfolio
-
Jennison Associates LLC11.1MShares$164 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$158 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$146 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$127 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.05MShares$104 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X05.01MShares$73.8 Million0.4% of portfolio
-
State Street Corp Boston, MA4.53MShares$66.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.31MShares$63.6 Million0.0% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY4.16MShares$61.3 Million0.69% of portfolio
Latest Institutional Activity in ARQT
Top Purchases
Top Sells
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Insider Transactions at ARQT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 08
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
3,847
-3.41%
|
$53,858
$14.03 P/Share
|
|
Aug 04
2025
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
6,330
-3.11%
|
$88,620
$14.33 P/Share
|
|
Aug 04
2025
|
Latha Vairavan SVP Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
89
-0.14%
|
$1,246
$14.33 P/Share
|
|
Aug 04
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
2,622
-2.27%
|
$36,708
$14.33 P/Share
|
|
Aug 04
2025
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
11,547
-1.26%
|
$161,658
$14.33 P/Share
|
|
Aug 01
2025
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-4.74%
|
$140,000
$14.3 P/Share
|
|
Aug 01
2025
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.52%
|
-
|
|
Jul 14
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
5,750
-4.74%
|
$86,250
$15.07 P/Share
|
|
Jul 14
2025
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750
+4.53%
|
-
|
|
Jul 10
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
23,000
-16.61%
|
$345,000
$15.05 P/Share
|
|
Jul 10
2025
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,000
+14.24%
|
-
|
|
Jul 01
2025
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
9,208
-8.42%
|
$119,704
$13.84 P/Share
|
|
Jun 18
2025
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,139
-8.48%
|
$131,807
$13.37 P/Share
|
|
Jun 13
2025
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect |
2,646
+8.79%
|
$34,398
$13.08 P/Share
|
|
Jun 12
2025
|
Bhaskar Chaudhuri Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,609
+0.87%
|
-
|
|
Jun 12
2025
|
Halley E Gilbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,609
+22.35%
|
-
|
|
Jun 12
2025
|
Neha Krishnamohan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,609
+24.57%
|
-
|
|
Jun 12
2025
|
Terrie Curran Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,609
+30.01%
|
-
|
|
Jun 12
2025
|
Keith R Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,609
+22.35%
|
-
|
|
Jun 12
2025
|
Patrick J Heron |
BUY
Grant, award, or other acquisition
|
Direct |
7,609
+22.35%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 475K shares |
|---|---|
| Open market or private purchase | 32.2K shares |
| Bona fide gift | 1.99K shares |
| Exercise of conversion of derivative security | 90.5K shares |
| Bona fide gift | 1.99K shares |
|---|---|
| Open market or private sale | 518K shares |